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Abstract
Background: Putatively active drugs are often intraventricularly administered to gain direct access to brain and circumvent the
blood-brain barrier. A few studies on the normal central nervous system (CNS) have shown, however, that the distribution of
materials after intraventricular injections is much more limited than presumed and their exit from cerebrospinal fluid (CSF) is
more rapid than generally believed. In this study, we report the intracranial distribution and the clearance from CSF and adjacent
CNS tissue of radiolabeled insulin-like growth factor-1 after injection into one lateral ventricle of the normal rat brain.
Methods: Under barbiturate anesthesia, 125I-labeled insulin-like growth factor-1 (IGF-1) was injected into one lateral ventricle
of normal Sprague-Dawley rats. The subsequent distribution of IGF-1 through the cerebrospinal fluid (CSF) system and into
brain, cerebral blood vessels, and systemic blood was measured over time by gamma counting and quantitative autoradiography
(QAR).
Results: Within 5 min of infusion, IGF-1 had spread from the infused lateral ventricle into and through the third and fourth
ventricles. At this time, 25% of the infused IGF-1 had disappeared from the CSF-brain-meningeal system; the half time of this
loss was 12 min. The plasma concentration of cleared IGF-1 was, however, very low from 2 to 9 min and only began to rise
markedly after 20 min. This delay between loss and gain plus the lack of radiotracer in the cortical subarachnoid space suggested
that much of the IGF-1 was cleared into blood via the cranial and/or spinal nerve roots and their associated lymphatic systems
rather than periventricular tissue and arachnoid villi. Less than 10% of the injected radioactivity remained in the CSF-brain system
after 180 min. The CSF and arteries and arterioles within the subarachnoid cisterns were labeled with IGF-1 within 10 min.
Between 60 and 180 min, most of the radioactivity within the cranium was retained within and around these blood vessels and
by periaqueductal gray matter. Tissue profiles at two sites next to ventricular CSF showed that IGF-1 penetrated less than 1.25
mm into brain tissue and appreciable 125I-activity remained at the tissue-ventricular CSF interface after 180 min.
Conclusion: Our findings suggest that entry of IGF-1 into normal brain parenchyma after lateral ventricle administration is
limited by rapid clearance from CSF and brain and slow movement, apparently by diffusion, into the periventricular tissue.
Various growth factors and other neuroactive agents have been reported to be neuroprotective within the injured brain after
intraventricular administration. It is postulated that the delivery of such factors to neurons and glia in the injured brain may be
facilitated by abnormal CSF flow. These several observations suggest that the flow of CSF and entrained solutes may differ
considerably between normal and abnormal brain and even among various neuropathologies.
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Background
Insulin-like growth factor-1 (IGF-1) is present in brain
and cerebrospinal fluid (CSF) [1,2]. Its expression and the
distribution of its receptors have been shown to change
dynamically during development and differentiation [3],
implying that IGF-1 is involved in these processes within
the central nervous system (CNS). Hinting at some neu-
ropathological role, CSF levels of IGF-1 have been shown
to rise in several diseases, most notably with pituitary
tumors [4,5]. Recently, IGF-1 has been used in some stud-
ies for its putative neuroprotective effects and has been
suggested to be a potential therapeutic agent in many dis-
orders of the nervous system including amyotrophic lat-
eral sclerosis, Alzheimer's disease, and cerebral ischemia
[6].
The routes of IGF-1 administration have varied among
experimental studies and conditions, but intraventricular
injections have often been employed, especially for the
treatment of ischemic injury [7-12]. The intraventricular
approach bypasses the blood-brain barrier (BBB) and
implicitly assumes direct access of the injected material to
most, if not all, brain tissue. Calling this assumption into
question, however, are reports that show rapid, nearly
complete clearance of intraventricularly injected radiola-
beled sucrose, polyethylene glycol (PEG4000; MW = 4000
Da) and 40-amino acid amyloid peptide (Aβ 1–40) from
CSF and brain into blood [13,14]. These studies also indi-
cated that the small amount of radiolabeled material
remaining in brain after 1–3 hr (<10% of injected) was
mostly in the walls and/or perivascular spaces of the pial
arteries and arterioles within the subarachnoid cisterns
and in the tissue around the aqueduct of Sylvius [13,14].
The efficacy of delivery into brain via the CSF, has also
been challenged by the finding that diffusion of higher
molecular weight compounds from ventricular fluid into
brain is restricted by the ependyma [15]. Smaller com-
pounds (MW<5000 Da), however, readily permeate the
ependyma, but their subsequent penetration into the
parenchyma is limited by factors such as their restricted
rate of diffusion through the tortuous interstitium, tran-
scapillary loss, and cellular uptake and binding [16-18].
The neurobiological effects of intraventricularly injected
substances are widely accepted, but the preceding obser-
vations suggest that the pathways, rates of distribution
and sites of action within the neuraxis of such agents may
be more complex, perhaps more limited, than assumed.
Understanding the nature of such distribution may help
explain the normal pathways of CSF flow and its
entrained substances and the function and malfunction of
this specialized brain fluid system, the so-called "third
circulation."
In the present study, the distribution of 125I labeled IGF-1
(MW = 7430 Da) among CSF, brain, and blood between
2 min and 3 hr after a bolus intraventricular injection was
investigated in rats. The hypothesis to be tested was that
most of the intraventricularly injected peptide, IGF-1,
would be quickly cleared from the CSF and brain into
blood and that the remaining amount of IGF-1 would not
be widely or uniformly distributed within brain.
Methods
For these studies, 125I-IGF-1 (specific activity, 2 mCi/
mmol; MW = 7430 Da) and 125I microscales were pur-
chased from Amersham Life Sciences, USA. Male Sprague-
Dawley rats weighing 300–350 g were obtained from
Charles River (Cambridge, MA). All surgical procedures
and experiments were performed according to National
Institutes of Health guidelines under an approved proto-
col from the Institutional Animal Care and Use Commit-
tee of the Henry Ford Health System.
Intraventricular injections
Intraventricular injections were made according to the
methods previously described [13,14]. Briefly, one femo-
ral vein and artery were cannulated under halothane
anesthesia for subsequent injection of anesthetic agent
(40 mg/kg; Nembutal sodium, Abbott Laboratories, Chi-
cago, IL) and for sampling blood, respectively. After firmly
positioning the head in a stereotaxic frame, 200–500 nCi
of 125I-IGF-1 in either 0.5 or 1.0 µL saline was infused at
the rate of 1.0 µL/min into the anterior horn of one lateral
ventricle via a syringe pump (Sage Instruments: Model
351, Cambridge, MA). Stereotaxic coordinates for the
infusion were: antero-posterior = 0.0 relative to bregma;
lateral = 1.5 mm to the midline; and depth = 4.5 mm
down from the surface of the skull. After infusion, the can-
nula was left in place for the duration of the experiment
(n = 4–5 for each duration). Arterial blood samples were
collected at pre-designated intervals. Animals were decap-
itated at times ranging from 2–180 min after injection,
and the whole head was instantly frozen in 2-methylbu-
tane cooled to minus 45°C.
Despite careful usage of the above stereotaxic coordinates,
the infusate was sometimes delivered mainly into the
brain parenchyma. Such infusions became obvious upon
viewing the autoradiograms (ARG's). Any parenchymal
injections (i.e., those missing the ventricle) were due to
manual errors and were unintentional (n = 2–3). Data
from such experiments were analyzed separately from
those with intraventricular injections and some of these
findings will be reported.
Assessing organ and fluid radioactivity
The brains with accompanying CSF and blood plus sur-
rounding meninges were dissected from the frozen headCerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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without thawing. Working within a chest freezer set at -
20°C, the upper part of the skull was carefully removed
with a rongeur. This frozen specimen contained virtually
all of the intracranial contents and radioactivity. Immedi-
ately after removal, the frozen brain-meningeal-CSF spec-
imens were placed in bottles chilled to -80°C and counted
in a gamma counter (Wallac 1480, Turku, Finland). These
data were used to calculate the clearance of 125I-radioactiv-
ity from the CSF-brain-meningeal system. Plasma was
obtained from the blood samples, and radioactivity per
unit volume of plasma determined. These samples were
employed to track the appearance of radioactivity in
blood following administration. Samples of urine, kid-
ney, liver, and muscle were also assayed for radioactivity
by gamma counting. In all instances, the counts were cor-
rected for decay of 125I-activity. In a separate group of
anesthetized rats (n = 4), subarachnoidal CSF was col-
lected from the cisterna magna at several times after 125I-
IGF-1 infusion. Acid precipitability of radioactivity was
assessed on these specimens as well as on samples of
plasma and urine from all the animals. All data obtained
by gamma counting was calculated in units of dpm. Data
obtained by quantification if autoradiographic images
were calculated in nCi/g.
The procedure for obtaining the venous input rate,
referred to hereafter as the emergence function, was simi-
lar to one used by Patlak and Pettigrew [19] to establish
intravenous infusion schedules that yield specific arterial
time-course [20,21]. First, a very rapid intravenous bolus
injection was made and a carefully chosen series of well-
timed blood samples were obtained: every 5–10 seconds
for the first minute, every minute over the next 4 min, and
then at longer intervals over the next hour or more. This
curve depended on the distribution and clearance of the
material throughout the body as well as the intravenous
input function. A transfer function or transform that links
the bolus intravenous injection to the experimentally
determined arterial time-course was obtained. Then the
reverse was done, namely, the transfer function was
applied via the convolution integral to the arterial time-
course measured after intraventricular infusion, thus gen-
erating the emergence function. In this operation, the
transfer function took into account the whole body distri-
bution and fate of the cleared material once it has entered
the veins draining the site of injection including plasma
protein binding and urinary excretion.
As just indicated, to obtain the emergence function, it was
first necessary to determine the arterial time-course of
radioactivity after a certain input into a systemic vein. To
accomplish this, two rats were given an intravenous bolus
of 125I-IGF-1 (~1.2 µCi). Eighteen blood samples of 20–
25 µl each were drawn at a preset times between 5 sec and
60 min after the bolus. Plasma was obtained from the
blood samples, and radioactivity per unit volume of
plasma was determined.
Autoradiography
After measuring total radioactivity as indicated above, the
frozen brain-CSF-meningeal specimens were covered in
cold embedding matrix (M-1; Lipshaw, Pittsburgh, PA)
and stored at -80°C in sealed plastic bags until the time of
sectioning. Using a cryostat set at -19°C and starting at the
caudal end, the embedded brains were serially cut at 400
µm intervals into sets of five 20 µm thick sections. The first
and fifth sections were picked up on a slide for subsequent
Nissl staining; these histologies were used to identify the
areas of interest. The second, third and fourth sections in
the series were collected on chilled, numbered coverslips
for autoradiography. The next fifteen sections were dis-
carded, and the cycle was repeated up to the beginning of
the olfactory tubercles. The coverslips were placed on a
slide warmer at 60°C, which instantly dried and affixed
the frozen sections. The coverslips plus a set of 125I-micro-
scales (standards calibrated in nCi/g) were placed into an
x-ray cassette along with a sheet of Kodak Biomax MR-1
film. After sufficient time of exposure (20 – 25 days), the
films were developed.
Image analysis
The autoradiographic images were digitized and visual-
ized with an imaging system (Model AIS, Imaging
Research Inc., St. Catharines, Canada). The matching
Nissl stained sections were simultaneously displayed via a
microfiche reader (Eye Communication Systems, Inc.,
Hartland, WI). Areas with appreciable amounts of radio-
activity were located. These brain regions were demar-
cated on the histologies, and their exact location
identified with a rat brain atlas [22].
Using the known values of the 125I-standards, a standard
curve of optical density versus radioactivity in nCi/g was
constructed for each autoradiograph. The optical densities
of the tissue sections on the autoradiographs were con-
verted into radioactivity units (nCi/g) using the standard
curve and the radioactivity for the regions of interest was
calculated. As indicated above, the quantity of injected
radioactivity was varied among the experiments, with the
greater amount infused for the longer times. This proce-
dure led to adequate levels of radioactivity for accurate
assaying in all experiments. For data analysis and presen-
tation, all the values were normalized to 50 nCi per initial
infusion.
To determine the distribution from lateral ventricle and
aqueduct into brain, profiles of tissue radioactivity were
constructed. A rectangle was drawn on the digitized image
perpendicular to the ependymal border and extending 2
mm into the adjacent tissue. Radioactivity along thisCerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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rectangle was measured at every 0.25 mm and a plot of
radioactivity versus the distance was created. The areas
under the curve for such plots were calculated using the
trapezoid rule.
All data are reported as the mean ± SD.
Results
Clearance of 125I-IGF-1 from CSF and brain
Following accurate intraventricular administration (Fig.
1A, B), total intracranial radioactivity (brain-CSF-menin-
geal specimens) at 2 min after administration was approx-
imately 93% of the amount infused, indicating complete
or near complete delivery (Fig. 2). About 25% of the
injected label was cleared from the system during the first
5 min and nearly 80% by 30 min. During the next 150
min, an additional 12% was cleared. When the infusion
into one lateral ventricle was on target, the disappearance
of  125I-radioactivity from the intracranial compartment
was seemingly biphasic with half times and clearance frac-
tions of 10 and 180 min and 79% and 21%, respectively.
Almost all the radioactivity in the CSF drawn from the
live, anesthetized rats was TCA-precipitable and presumed
to be linked to IGF-1.
In 12 of 75 infusions, much of the radioactivity was acci-
dentally deposited directly into the parenchyma (Fig. 1C,
D). In these cases, the subsequent clearance of 125I-activity
from the brain-CSF-meningeal specimen was different
than that following direct intraventricular administration
(Fig. 2). The data from these 12 rats suggest a rapid and
sizable decrease (30% loss) of intracranial radioactivity
over the first 5 min (the first time of sampling for this
group of rats; n = 1) and a slower but larger decrease (40%
loss) over the next 40 min. It is likely that most of this
clearance was of IGF-1 delivered into the CSF. There was
essentially no further loss of radioactivity from the brain-
CSF-meningeal system over the remaining 135 min (Fig.
2). During this phase, most of the radioactivity was
located in the tissue around the injection site dorsal to the
lateral ventricle. Infusion into the parenchyma caused
some swelling of the corpus callosum, the white matter
structure that received much of the infusate (Fig. 1C).
These observations are indicative of the distribution and
tissue injury obtained when agents and tracers are deliber-
ately or accidentally administered into the parenchyma
[23,24].
With both intraventricular and intraparenchymal infu-
sions, low but significantly greater than background
amounts of radioactivity were detected in the blood at 5
and 9 min (Fig. 3). Plasma 125I-activity rose sharply after
20 min in both cases and levelled off after 90 min, albeit
at a much lower concentration for the intraparenchymal
than intraventricular infusions (600 and 900 dpm/ml,
respectively). Between 90 and180 min, the concentration
in blood was essentially constant.
For the arterial time-course following an intravenous bolus
of  125I-IGF-1 (required to find the emergence function
along with the preceding data), plasma radioactivity had
begun to rise by 15 sec, reached a peak around 25 sec,
dropped precipitously over the next several min, and
slowly declined from 10–60 min (Fig. 4A). The rate of
125I-appearance in venous blood (emergence function,
dpm per min) was low at 5 min (the earliest time with sig-
nificant plasma radioactivity) but it was higher for intra-
parenchymal (221 dpm/min) than intraventricular (185
dpm/min) injections (Fig. 4B; rate given on the ordinate).
After 7.5 min, the rate increased markedly, reaching a
peak at approximately 40 min of 1665 dpm/min with
intraventricular injection and 924 dpm/min with intrapa-
renchymal administration. The emergence rates fell con-
tinuously thereafter, but good estimates beyond 60 min
were not possible because of the low radioactivity and the
flatness of the post-bolus blood curve from 45 min
onward (Fig. 4A).
The lag between the rapid disappearance from the brain-
CSF-meningeal specimen from 2 min to 30 min (Fig. 2)
and the marked rise in blood concentration after 20 min
(Fig. 3) is a bit surprising. This discrepancy suggests that
most of the 125I-IGF-1 clearance from the intracranial
compartment did not directly and immediately pass into
blood across the capillaries of the structures around and
within the ventricles, such as the choroid plexuses, sub-
ependymal zone, and circumventricular organs (e.g., the
subfornical organ and median eminence).
Among the three tissues sampled and urine, 125I-activity
was at or near background at 2 and 5 min in all four (Fig.
5) and remained very low up to 20 min for liver, muscle,
and urine. The radioactivity was somewhat elevated in the
kidney at 9 and 20 min and thereafter arose slightly in the
liver and much more in the kidney, and urine. Uptake of
125I by muscle, the largest organ in the body, was slow and
slight. None of the 125I-activity in urine was TCA-precipi-
table, but 30–50% of that in plasma was. These findings
demonstrate that little of the 125I-activity cleared from the
brain-CSF-meningeal samples over the first 10 min passed
immediately into blood or into non brain tissues and
urine. Therefore the low plasma levels of radioactivity
from 2–9 min (Fig. 3) were not the result of rapid systemic
tissue uptake and urinary excretion.
Distribution of IGF-1 radioactivity within the CSF system
Two min after infusion into one lateral ventricle, CSF-con-
tained radioactivity was already present in the third ven-
tricle (Fig. 6A) and aqueduct (Fig. 6B), but the optical
densities at these two sites were too high for accurateCerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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quantitation. This was also true for the ipsilateral lateral
ventricle. The concentrations of 125I-IGF-1 at 5 min were
~10,000 nCi/g in the CSF retained within the ipsilateral
lateral ventricle and ~6000 nCi/g in that within the third
ventricle and aqueduct (Fig. 7). Indicative of relatively
rapid CSF flow, radioactivity fell sharply thereafter in
these three CSF compartments, reaching low levels by 30
min, and becoming very low (<200 nCi/g) by 180 min.
Between 2 and 5 min, most of the intracranial 125I-IGF-1
was present in the CSF within the lateral and third ventri-
cles and the aqueduct. There was some early mixing of the
injected radioactivity into the contralateral lateral ventri-
cle (data not shown). The concentration of 125I IGF-1
within the fourth ventricle was appreciable at 5 min (Fig.
Nissl-stained histologies (A and C) and adjacent autoradiograms (ARG's; B and D) showing the lateral (LV) and the third (3 V)  ventricles 30 min after injection into one lateral ventricle (A and B, respectively) or into the parenchyma (C and D,  respectively) Figure 1
Nissl-stained histologies (A and C) and adjacent autoradiograms (ARG's; B and D) showing the lateral (LV) 
and the third (3 V) ventricles 30 min after injection into one lateral ventricle (A and B, respectively) or into the 
parenchyma (C and D, respectively). 1A. This histological section is at bregma -0.2 mm and cuts through the cerebral 
cortex (not labeled), LV, caudate-putamen (CPU), 3 V, anterior commissure (not labeled), and the optic chiasm (missing on the 
histology, but evident on the ARG, 1B). 1B. The lateral ventricle choroid plexus and the walls of the LV and 3 V on the ipsilat-
eral side are darkly labeled on this ARG, but little radioactivity is evident in the ventricles. The flattened loop of moderate 
darkness at the very bottom of the ARG demarcates the subarachnoid space around the optic chiasm. The dark half-ring or 
crescent above the optic chiasm partially surrounds the medial nucleus of the preoptic area, a peculiar pre-hypothalamic struc-
ture; this crescent appears to be an extension of the ventral part of the 3 V but may be an artifact. 1C. This section is at 
bregma -0.3 mm and passes through the same structures as 1A above. Notable on this histology are the needle tract and cor-
pus callosum, which on the ipsilateral side below the tract is expanded, pale, and edematous. 1D. Most of the radioactivity in 
this ARG is contained in the tissue near the main site of the intraparenchymal infusion, but some is in the choroid plexus and 
CSF (both shown by the tail below the main patch of blackness on the ARG). Much of the tissue radioactivity is in the corpus 
callosum and some of it extends via this white matter tract across the midline. Scale bar = 1.5 mm.Cerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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7), reached a maximum (>2000 nCi/g) at 10–20 min, and
fell gradually thereafter.
Radioactivity in the quadrigeminal, ambient, and interpe-
duncular cisterns, parts of the midbrain subarachnoidal
system, was essentially zero for the first five minutes but
was detectable, albeit low, from 10–20 min (Figs. 7 and
8B); it rose rapidly from 20 to 45 min (~5700 nCi/g) and
then fell over the next 135 min (Fig. 7). Over the 20–180
min period, much of the intracranial radioactivity was
localized around the arteries and arterioles within these
and other cisterns (Fig. 8A and 8B). This radioactivity
could be in either the perivascular sheath, which contains
CSF, or the vessel wall or both.
As we have reported for 14C-sucrose, 14C-PEG4000, and
125I-amyloid β peptide (Aβ1–40) [13,14], the radioactiv-
ity in the midbrain subarachnoid cisterns during the first
20 min appeared to come mostly from the third and
fourth ventricles via the velum interpositum (Fig. 9A) and
anterior medullary velum (Fig. 9B), respectively. These
two velae are extensions of the subarachnoid space and
form part of the membranous covering of these two ven-
tricles. Once the CSF-entrained radioactivity moved from
ventricle into these velae, it flowed from the velum inter-
positum and the superior medullary velum into the quad-
rigeminal, ambient and the interpeduncular cisterns. The
sharp rise in midbrain cisternal 125I-IGF-1 from 20–45
min (Fig. 7) probably is mainly due to CSF flow via the
"classic" route; that is, from the lateral recesses of the
fourth ventricle through the foramina of Magendie and
Luschka and into the cisterna magna and the subarach-
noidal cisterns around the brain stem.
At longer times (e.g., 90 min; Fig. 8D), an appreciable
uptake and retention of 125I-IGF-1 was evident for some of
the tissues adjacent to the array of midbrain cisterns;
among these tissues are the medial geniculate (a thalamic
nucleus), the basal part of the cerebral peduncles, and the
dentate gyrus of the hippocampus. Again as in our other
studies, no radioactivity could be seen in the subarach-
noid space over the cerebral cortices.
Periventricular and periaqueductal tissue profiles
The tissue profiles of radioactivity indicated that the
ependyma is not a significant barrier to the movement of
IGF-1 from CSF into gray matter. This is evidenced by the
sizable amounts of radiolabel that moved within the first
5 min as far as 500 µm into periventricular tissue,
The percentage of radioactivity remaining in the entire sys- tem of frozen brain, blood, CSF, and meninges over time fol- lowing either intraventricular or intraparenchymal infusion of  125I-IGF-1 Figure 2
The percentage of radioactivity remaining in the 
entire system of frozen brain, blood, CSF, and 
meninges over time following either intraventricular 
or intraparenchymal infusion of 125I-IGF-1. There were 
4–5 experiments per mean and time for the intraventricular 
infusions but only 2–3 for the intraparenchymal ones, which 
were accidental and not intended. Data are shown as mean ± 
SD. The initial phase dominated the first 30 min of clearance 
and accounted for most of the loss from the system for both 
sets of infusion data. From 45 min onward, virtually no radio-
activity was lost from the system with the intraparenchymal 
infusion, whereas 125I-activity declined very slowly with intra-
ventricular infusion (40% decline from 45 to 180 min).
Plasma radioactivity over time after infusions into the lateral  ventricle and parenchyma Figure 3
Plasma radioactivity over time after infusions into 
the lateral ventricle and parenchyma. Data are shown 
as mean ± SD. Plasma concentrations were fairly similar for 
both infusions up to 20 min, when the intraventricular infu-
sion began to yield higher radioactivity; plasma concentra-
tions for intraventricular infusions were about 50% higher 
than those for intraparenchymal infusion at 90–180 min. 
These data plus those in Fig. 2 clearly show the much greater 
clearance of intraventricularly infused 125I-IGF-1.Cerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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exemplified in this study by the caudate-putamen (Fig.
10A), and 250 µm into periaqueductal gray matter (Fig.
10B). These distances are reasonable for free diffusion
through the tortuous extracellular space of the brain for
such a duration and molecule. The differences in the
amounts of radioactivity and its spread into the paren-
chyma between these two areas is caused by the 1–2 min
delay in delivery to the aqueduct and the lower 125I-con-
centration within it (Fig. 7). The latter is the result of dilu-
tion within the third ventricle by inflowing unlabeled CSF
from the contralateral lateral ventricle and by production
of fresh CSF by the third ventricle choroid plexus.
As the CSF concentration falls within the ventricular sys-
tem over time, the profiles flatten for both tissues sites.
This decline is driven by a combination of backflux of
unbound radiolabel from tissue to adjacent CSF and
movement further into the tissue (see the legend to Fig. 10
for more on this). At all times and both tissue sites, 125I-
activity decreased over distance into the brain and reached
a plateau around 1.5–2.0 mm for caudate-putamen (Fig
10A) and 1.0–1.5 mm for periaqueductal gray matter (Fig.
10B). Indicating a net loss of IFG-1 over time, the mean
area under the tissue radioactivity-distance curve over 2.0
mm for the caudate-putamen was highest at 5 min (2757
Calculation and graphing of the emergence function, i.e., the  rate of appearance of 125I-activity in venous blood Figure 4
Calculation and graphing of the emergence function, 
i.e., the rate of appearance of 125I-activity in venous 
blood. 4A. The time-course of radioactivity concentration 
in arterial plasma after an intravenous bolus injection of 125I-
IGF-1. 4B. The emergence function calculated from the arte-
rial plasma concentration-time curve following intravenous 
injection plus the arterial plasma curves following intraven-
tricular and intraparenchymal infusions. The emergence func-
tion is the rate of appearance of the radioactivity in the 
venous system (dpm/min) and was calculated for 2.5, 7.5, 15, 
25, 37.5, 52.5, and 75 min; the breakpoints on the graphs 
demarcate these times after infusion. The curves were not 
smoothed although the rates continually change throughout 
the period of interest.
IGF-1 radioactivity in kidney, liver, skeletal muscle and urine  after its intraventricular injection Figure 5
IGF-1 radioactivity in kidney, liver, skeletal muscle 
and urine after its intraventricular injection. Kidneys 
were always seen to preferentially sequester IGF-1 from 
blood in the first 90 min after injection. Appreciable amounts 
of radioactivity began to appear in the urine after an initial lag 
period of ~5 min. After 20 min, radioactivity in urine rose 
almost linearly with time whereas that in the kidneys began 
dropping after 90 min. Liver and skeletal muscle had compar-
atively very little radioactivity throughout the period of 
study. The inset shows the tissue radioactivity for the first 20 
min that may not be evident on the main graph. All data are 
mean ± SD at the various times.Cerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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Nissl-stained histologies (A and C) and adjacent autoradiograms (ARG's; B and D) showing the third ventricle (A and B, respec- tively; bregma -3.3 mm) and aqueduct of Sylvius (C and D, respectively; bregma -7.6 mm) 2 min after infusion of 125I-IGF-1 into  one lateral ventricle (LV) Figure 6
Nissl-stained histologies (A and C) and adjacent autoradiograms (ARG's; B and D) showing the third ventricle 
(A and B, respectively; bregma -3.3 mm) and aqueduct of Sylvius (C and D, respectively; bregma -7.6 mm) 2 
min after infusion of 125I-IGF-1 into one lateral ventricle (LV). 6A. This histological section cuts through the parietal 
cortex, hippocampus, and thalamus (the large, light gray mass below the hippocampus) as well as the third ventricle (3 V), 
which is torn at its ventral border. The latter is formed by the very thin median eminence, which is one of the circumventricu-
lar organs and often tears during sectioning. 6B. The ARG indicates considerable delivery of radioactivity to the dorsal (very 
dark and very full) and ventral parts of the 3 V within two min of ending the infusion. The lateral streak of black to the left of 
the dorsal 3 V is actually part of the latter that extends over the stria medullaris thalami, the white matter that forms the 
dorso-medial border of the thalamus. Some spreading of 125I-activity into the tissue adjacent to the ventral part of the 3 V is 
evident on the ARG at this time. The most ventral portion of this part of the 3 V flairs over the median eminence; the CSF in 
these little pockets explains, in part, the dark streaks radiating from the bottom of the ventral part of the 3 V and over the 
median eminence. The streak on the left seems, however, strangely long and has seldom been seen by us before. It may be real; 
it may be an artifact. 6C. This histological section passes through the pineal gland, the superior colliculus (midbrain) and subic-
ulum (cortical end of the hippocampus). The tiny dots surrounding the midbrain are clusters of small arteries and veins in the 
subarachnoid space and cisterns; at this level, the latter are the quadrigeminal (dorsal) and ambient (lateral) cisterns. 6D. This 
ARG shows a very high level of radioactivity in the CSF within the aqueduct after only 2 min of circulation and indicates the 
speed at which CSF flows from the lateral ventricle through the 3 V system, which includes many recesses, and into the aque-
duct. Scale bar = 1.5 mm.Cerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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nCi mm g-1) and fell continuously thereafter reaching
1293 nCi mm g-1 at 180 min. In contrast, the mean area
under the curve for periaqueductal gray was lowest at 5
min (652 nCi mm g-1), rose to 955 nCi mm g-1 by 30 min,
and remained high at 180 min (922 nCi mm g-1).
Regional differences in the uptake and retention of IGF-1
are obvious from these two tissue profiles.
Discussion
Experimental procedure
The intraventricular route of IGF-1 administration was
selected because it has been used for many studies. Bolus
injections into one lateral ventricle of IGF-1 have been
reported, for instance, to improve neurological outcome
for both permanent and transient cerebral ischemia in rats
and other small laboratory animals [9-12]. A small bolus
was chosen for injection in order to cause a minimal and
transient disturbance of CSF pressure and flow.
Freezing the whole head immediately after decapitation
has been shown to prevent collapse of the ventricles and
preserve pre-mortem  blood and CSF distribution within
the cranial cavity [25]. A key part of this procedure is keep-
ing the head and its contents frozen while removing the
brain-CSF-meningeal specimen. The procedure is ardu-
ous, but these conditions minimize loss and post-mortem
movement of radioactivity. In contrast to our procedure,
others have removed the brain before freezing [15,26] or
have perfusion-fixed the brain before sectioning and auto-
radiography [27].
The emergence function is based on the assumption of
tracer kinetics; that is, the concentration of the radiotracer
is presupposed to be very low with respect to the cold
substrate, in this case, IGF-1. With this assumption, the
distribution of 125I-IGF-1 is considered to be a linear func-
tion of its concentration in CSF, brain, and blood. There
are IGF-1 binding proteins (IGFBP's) in the CNS and
blood [6] and undoubtedly a state of dynamic equilib-
rium exists between IGF-1 and its binding proteins.
Although 125I-IGF-1 concentrations were somewhat high
in the ventricular and intravenous infusates, it would be
diluted to tracer levels in plasma within seconds as it
mixes in the circulating blood and binds to plasma
proteins such as the IGFBP's. The tracer assumption for
the intravenous infusion may be violated for the first 30
seconds or so (systemic circulation time in the normal rat
is about 15 sec) but not thereafter. This dilution-mixing
process is probably slower in the CSF, but the amount of
125I-IGF-1 intraventricularly infused was considerably
lower, namely, around 25% of the intravenous dose, and
that enhances the tracer assumption on the CNS side.
Peculiarities in cerebrospinal fluid flow
Recent experiments indicate that about 25% of CSF and
CSF-borne radiolabeled sucrose [14], PEG4000 [13],
soluble amyloid beta peptide (sAβ1–40) [13], and IGF-1
(Fig. 9) flow into the subarachnoid extensions of the
velum interpositum (from the dorsal part of third
ventricle) and superior medullary velum (from the rostral
part of the fourth ventricle). Within 4–5 min, intravelar
CSF appears in the basal and midbrain cisterns and the
arteries and arterioles contained within them [14]. The
rest of the CSF flows from the sites of production within
the ventricles to and through the lateral recesses of the
fourth ventricle and the foramina of Luschka and Magen-
die into the cisterna magna. From there, this CSF passes
into the spinal and cranial subarachnoid space. It was also
noted in these three studies that very little of these radiola-
bel materials reached the cortical surface of the normal rat
brain even after three hours of circulation.
Within the basal cisterns, all four of these radiolabeled
materials accumulate in the pial arteries and arterioles.
Anatomically, these blood vessels seem to be surrounded
by a specialized pia-arachnoid membrane complex that
functions to trap CSF-borne substrates. In addition, the
Distribution of 125I-IGF-1 radioactivity in five CSF compart- ments as a function of time after ending the infusion Figure 7
Distribution of 125I-IGF-1 radioactivity in five CSF 
compartments as a function of time after ending the 
infusion. The data are shown as mean ± SD at the various 
times. The first two sets of points are at 5 and 9 min. By 5 
min, the peak concentrations have already passed through 
the lateral and third ventricles and the aqueduct; at 30 min, 
125I-IGF-1 in these three compartments has fallen to <750 
nCi/g. Radioactivity in the fourth ventricle reached a plateau 
over the 9–20 min period and dropped thereafter. In the 
midbrain cisterns, 125I-IGF-1 sharply rose from 20 to 45 min 
and then fell continuously thereafter. The peak radioactivity 
at 45 min is notable, exceeding that in the 4th ventricle by 5-
fold. These curves show that 125I-IGF-1 moved relatively 
briskly through the ventricular system.Cerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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highly vascular choroid plexuses were also observed to
take up and retain some IGF-1 for the first 30 min (Fig. 1B
and 5B). It should be noted that IGF-1 receptors are
present in rat choroid plexus [28]. It may be that one or
more of these vascular tissues are involved in the putative
neuroactive effects of IGF-1 (Figs. 1 and 7).
Of relevance to vascular involvement, gene transfer to the
adventitia and leptomeninges of arteries and arterioles
along the ventral surface of the brain has been
accomplished in mice via a recombinant adenovirus
injected into either one lateral ventricle or the cisterna
magna [29,30]. Such transfer was not, however, achieved
on the dorsal surface of the brain, which may be due to
the very low delivery of CSF-entrained substances over the
cortex as observed in other studies [13,14] as well as the
present one.
Nissl-stained histologies (A and C) and adjacent autoradiograms (ARG's) at 20 min after 125I-IGF-1 infusion (A and B, respec- tively; bregma -7.8 mm) and 90 min (C and D, respectively; bregma -6.8 mm) Figure 8
Nissl-stained histologies (A and C) and adjacent autoradiograms (ARG's) at 20 min after 125I-IGF-1 infusion (A 
and B, respectively; bregma -7.8 mm) and 90 min (C and D, respectively; bregma -6.8 mm). 8A. This section 
passes through the pineal gland, inferior colliculus (midbrain), aqueduct, and hippocampus and is just slightly caudal to Fig. 5C. 
Patches of small arteries and veins are scattered throughout the midbrain cisterns. 8B. The adjacent ARG shows some pene-
tration of radioactivity into periaqueductal gray matter at 20 min and a minute amount within the midbrain cisterns. 8C. About 
1.0 mm rostral to 7A, this section cuts through the superior colliculus, aqueduct, midbrain cisterns, dentate gyrus of the hip-
pocampus, and the pontine nuclei (the large mass hanging below the midbrain). 8D. The matching ARG, obtained at 90 min, 
indicates considerable retention of 125I-IGF-1 by the tissue immediately around the aqueduct and on both sides of the midbrain 
cisterns. The arteries and veins in the subarachnoid space also retain much radioactivity at this time. Scale bar = 1.5 mm.Cerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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Differences in the CSF-brain-blood distribution of peptides
Before proceeding further, an evaluation of the robustness
of these techniques and data is in order. The gamma
counting technique for the plasma and tissue radioactivity
is very straightforward and highly accurate. The delay of
several minutes before the elevation of both the plasma
Nissl-stained histologies (A and C) and adjacent autoradiograms (ARG's) at 30 min after 125I-IGF-1 infusion for the two sub- arachnoid velae, the velum interpositum (A and B, respectively; bregma -4.3 mm) and the superior (anterior) medullary velum  (C and D, respectively; bregma -9.2 mm) Figure 9
Nissl-stained histologies (A and C) and adjacent autoradiograms (ARG's) at 30 min after 125I-IGF-1 infusion for 
the two subarachnoid velae, the velum interpositum (A and B, respectively; bregma -4.3 mm) and the superior 
(anterior) medullary velum (C and D, respectively; bregma -9.2 mm). 9A. Starting at the subfornical organ and run-
ning caudad along the roof and upper sides of the third ventricle (3 V), the velum interpositum separates the 3 V from the sub-
arachnoid space within it. The 3 V is clear and featureless, whereas the velum interpositum is filled with typical arachnoid 
tissue, e.g., trabeculae and blood vessels. The thalamus is the brain structure comprising the lower half of the figure. 9B. At 30 
min, there was some radioactivity in the 3 V and the contralateral velum (left side) and much more in the ipsilateral velum. The 
dark spot at the bottom of the ARG came from 125I-activity within the mammillary recess of the 3 V. 9C. The superior medul-
lary velum (SMV) forms the posterior wall of the recess of the inferior colliculus (this recess is an outpouching ofthe aqueduct 
and not shown) and the anterior roof of the fourth ventricle, mostly in the vicinity of the cerebellum; it contains subarachnoid 
CSF and tissue. 9D. The very dark "A-shaped" figure in the middle of this ARG indicates radioactivity that has collected over 
30 min in the CSF and tissue of the SMV. The grayness within the legs of the upright "A" indicates some diffusion into the cer-
ebellar lobe from the SMV. The legs and crossbar of the inverted "A" in the lower middle of the ARG represent radioactivity 
within the SMV on the ventral side of the cerebellar lobe (the SMV is not visible on the histology at this magnification, Fig. 9C; 
it can be seen to be subarachnoid tissue in Fig. 6 of Ghersi-Egea et al. [14]. The lighter spot within the lower part of the 
inverted "A" arises from CSF signal within the fourth ventricle. The faint figures in the rest of this ARG indicate radioactivity in 
several midbrain cisterns of the subarachnoid system at 30 min. Scale bar = 0.6 mm.Cerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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(Figs. 3) and systemic tissue (Figs. 3, 4, 5) 125I-activity is
probably not an artefact. One possibility to consider is
that not all of the IGF-1 reached the lateral ventricle CSF
at injection and the initial rapid decline is caused by that
shortcoming. At 2 min, however, the earliest time of sam-
pling, around 93% of the radioactivity was still in the sys-
tem, and most of the decrease occurred subsequently.
Similar studies with 14C-sucrose [14] and 14C-PEG4000
[13] showed that virtually all the infused radioactivity was
present within the cranium for the first 5 min. On the
occasions when it was obvious from the autoradiograms
that the IGF-1 was partially or completely infused into the
brain parenchyma, those experiments were eliminated
from the successful group. It, thus, seems that there is little
or no problem with the accuracy of the intraventricular
infusion method.
In the present study, IGF-1 exited from the brain-CSF-
meningeal compartment at an unexpectedly fast rate. The
clearance of ~50% of it by 15 min and ~80% by 30 min is
far faster than that of sucrose [14] or PEG4000 [13] which
had no clearance over the first 5 min and apparent half-
lives ~60 min for both. Of the molecules studied to date,
only 125I-labeled soluble amyloid β peptide (I-sAβ1–40)
with a ~50% loss within 8 min [13], is cleared more rap-
idly than IGF-1. In another study, the half time of disap-
pearance from brain of insulin has been calculated as 26
min in mice [26].
Rapid clearance of IGF-1 and I-sAβ1–40 from the brain-
CSF-meningeal system would be expected to take place
directly into the circulating cerebral blood and lead to sys-
temic distribution. In the study with I-sAβ1–40 [13], this
was found to be the case: when arterial blood concentra-
tion of I-sAβ1–40 was measured 3.5 min after intraven-
tricular infusion, about 30% of the infused I-sAβ1–40 had
already been cleared from the brain-CSF-meningeal sys-
tem, and the blood level of 125I was high. With further
clearance over time, the concentration of I-sAβ1–40 in
blood continued to rise slowly, increasing by 25%
between 3.5 and 30 min. Consistent with this, the tissue
levels of 125I-activity were appreciable in liver at 3.5 and
10 min and even higher in the kidney at these two times.
Although emergence function analysis was not done on
these data, it was evident that the I-sAβ1–40 cleared from
the CSF-brain-meningeal system passed immediately into
the circulating blood and distributed throughout the
body. Because of the speed of this process, the clearance of
I-sAβ1–40 was assumed to be directly across the
capillaries of the choroid plexuses, the subependymal
zone, and other periventricular structures such as the cir-
cumventricular organs. This mechanism has been sug-
gested for not only sAβ1–40 but also other peptides and
immunoglobulins [13,31,32].
Tissue radioactivities as a function of distance (profiles) away  from the CSF-brain interface for the caudate-putamen (A)  and periaqueductal gray matter (B) at four times Figure 10
Tissue radioactivities as a function of distance (pro-
files) away from the CSF-brain interface for the cau-
date-putamen (A) and periaqueductal gray matter 
(B) at four times. The shapes of the curves and the con-
centration-distance integrals indicate two different tissue dis-
tribution dynamics. To illustrate this, we will consider only 
the 5 and 9 min profiles and avoid the matter of sizable tissue 
uptake from blood that affects the later times. For the cau-
date-putamen (10A), the 5 min points all lie above the 9 min 
ones out to 1.5 mm, where they both approach zero. The 
areas under these curves are 2757 (nCi/g) × mm at 5 min and 
2002 (nCi/g) × mm at 9 min; clearly there was a loss of radio-
activity, probably back into the CSF, over the 5–9 min 
period. In contrast, periaqueductal gray matter radioactivities 
(10B) were similar at the edge of the tissue (x = 0) at these 
two times but the 9 min points were higher than the 5 min 
ones from 0.25 to 0.75 mm, where both became essentially 
zero. The area under the 5 min curve was less than that 
under the 9 min one, 662 vs. 873 (nCi/g) × mm, respectively; 
periaqueductal gray matter, thus, continued to take up 125I-
IGF-1 even as concentration in aqueductal CSF was falling 
(Fig. 7). One explanation for this is greater binding or trap-
ping of IGF-1 in periaqueductal gray matter than in caudate-
putamen. Data are shown as mean ± SD.Cerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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In contrast, this study found an unexpected delay between
the loss of IGF-1 from the CSF-brain-meningeal system
and its appearance in blood. Although 35% of the infused
radioactivity was gone from the system after 9 min, the
plasma concentration was very low (less than 8% of the
maximum) at this time and at the preceding times of sam-
pling (Fig. 3). Thereafter the clearance of IGF-1 from the
CSF-brain-meningeal system continued, with only 20%
remaining by 30 min. Plasma radioactivity increased
between 9 and 20 min, more sharply between 20 and 30
min, and even more steeply between 30 and 45 min,
finally reaching a plateau at 90 min (Fig. 3). Reflecting
this delayed, slow increase in blood radioactivity, the
emergence rate for IGF-1 (Fig. 4) began to increase
between 9 and 12 min and then climbed markedly
between 12 and 20 min.
A study on the clearance of a biologically inert and extra-
cellular compound 14C-PEG4000 (MW = 4000 Da) fol-
lowing intraventricular infusion [13], showed that the
compound was retained in higher concentration in the
CSF system at early time points than for IGF-1, but a sim-
ilar delay occurred before it appeared in blood. Since the
PEG clearance pathway is probably non-specific and it is
most likely lost by CSF bulk flow and absorption, it is pos-
sible that a sizable portion of the infused IGF-1 could also
have been cleared via this route. However, the delay in
appearance in blood in both studies indicates that the
compounds lost from the brain-CSF-meningeal system at
the early time points did not go directly into the circulat-
ing cerebral blood.
Hence the temporal mismatch of IGF-1 clearance from the
CSF-brain-meningeal and its appearance in systemic
blood remains enigmatic. A small part of the initial clear-
ance of IGF-1 does seem to be directly into blood via the
periventricular tissue and choroid plexuses as occurs with
sAβ1–40. A much larger portion of it may flow rather rap-
idly out of the cranial space via the PEG-CSF pathway. The
time-course and magnitude of this is suggested by the
steep rise in the rate of appearance in systemic blood that
starts after 9 min and peaks at 40 min (Fig. 4B). Much of
this bulk CSF clearance may be by way of the cranial nerve
sheaths and the cranial and cervical lymphatic systems as
has been shown for albumin [33,34] or by passage from
the cisterna magna into the spinal subarachnoid space,
which is outside of our sampling field, and hence into the
venous system. One or the other or both of these putative
routes could be the physiological explanation of the delay
in the IGF-1 appearance in blood.
Tissue profiles
The tissue profiles showed some penetration of IGF-1 into
the brain immediately adjacent to the CSF (Fig. 9A, cau-
date-putamen; Fig. 9B, periaqueductal gray matter) over
the first 9 min when blood-contained radioactivity was
low (Fig. 3). At these times, little or no radioactivity had,
however, moved beyond 1.0 mm in the caudate-putamen
and 0.5 mm in periaqueductal gray matter. At 30 and 180
min, the concentrations of radioactivity in the ependymal
and subependymal tissue were much higher than in the
adjacent CSF (Fig. 6), and the radioactivity at the
peripheral zone was three-times higher than the deeper
tissue plateau concentration. Collectively, these observa-
tions suggest that 125I-IGF or some labeled metabolite(s)
is "trapped" in this tissue, perhaps to a receptor or within
some periventricular intracellular compartment.
The implication of this is that for intraventricularly
injected IGF-1 to be centrally effective it either interacts
with receptors or compartments that are immediately
around the ventricular system or works at deep active sites
at the low levels indicated by the 30–180 min 125I-IGF-1
plateaux (Fig. 9). Recent work has shown the presence of
neuronal progenitor cells in the subependymal layer
(a.k.a., the subventricular zone), especially of the lateral
ventricles and dentate gyrus of the hippocampus [35,36].
Such cells are well positioned with respect to circulating
CSF and could be the target of CSF-borne growth factors.
Intraventricular IGF-1 delivery following brain injury
Injury to the brain might result in changes to the flow of
CSF and affect the distribution of intraventricularly
administered peptides into brain. For example, 2 hr after
hypoxic-ischemic injury, tritiated IGF-1 was intraventricu-
larly infused for 30 min and immediately thereafter was
found in the ipsilateral cerebral cortex [37]; this cortical
radioactivity decreased over the next 6 hr and reached
background (the contralateral level) after 12 hr. Microau-
toradiography indicated that 3H-IGF-1 was also present in
the corpus callosum and its ventral extension, the external
capsule, plus the perivascular (Virchow-Robin) spaces
that surround the penetrating arteries and arterioles of the
cortex 30 min after ending the infusion. This contrasts
with our findings for normal brain of little or no IGF dis-
tribution to the cerebral cortex and underlying white mat-
ter. On the other hand, in our experimental "mistakes" in
which much of the infusate was placed in the parenchyma
causing trauma, the white matter was also heavily labeled
with  125I-IGF-1 at all times of sampling (30 min data
showed in Fig. 1D).
As to clearance into systemic blood, the serum concentra-
tion of 3H-IGF-1 in the studies of Guan et al [37] was high
at 30 min after beginning the infusion in both hypoxia-
ischemia injured rats and uninjured controls and rose 3-
fold and 5-fold, respectively, over the next 3 hr. This
resembles the plasma data given in Figure 3 for the intra-
parenchymal (accidental) and intraventricular infusion
groups.Cerebrospinal Fluid Research 2005, 2:5 http://www.cerebrospinalfluidresearch.com/content/2/1/5
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In a later study with the same hypoxia-ischemia model
and intraventricular infusion protocol, Guan et al [38]
investigated the cellular distribution of 3H-IGF-1 and its
co-localization with immunoreactive IGFBP-2 at 30 min
and 6 hr after administration. Thirty min after ending the
infusion of 3H-IGF-1, it was mainly found in the pia
mater, the perivascular spaces (extensions of the external
subarachnoid space), and subcortical white matter struc-
tures such as the corpus callosum. The addition of cold
IGF-1 to the infusate diminished the distribution of radi-
otracer to white matter tracts but not to the pia mater and
perivascular spaces. Within subcortical white matter,
tritiated IGF-1 co-localized with IGFBP-2 immunoreactiv-
ity and was seen at the microautoradiographic level to be
associated with fiber tracts and some oligodendrocytes. In
the cerebral cortex 30 min after completing the infusion,
the 3H-signal was diffusely distributed but evident on the
neurons of layers II-V, glia (astrocytes or microglia were
not specified), and the extracellular matrix. On the basis
of these data and the earlier study [37], the authors
suggested for this model of hypoxia-ischemia that: 1) such
patterns of IGF-1 distribution were not compatible with
simple diffusion and were likely to be abnormal; 2) bulk
flow of CSF through the ependyma and along white
matter tracts and also through the subarachnoidal perivas-
cular spaces carried IGF-1, in some cases in association
with IGFBP-2, to the neurons and glia of the injured cere-
bral cortex; and 3) this abnormal flow of CSF promotes
the delivery of intraventricularly administered therapeutic
agents to damaged tissue sites.
Our findings are consistent with this postulate in several
somewhat indirect ways. The observations on normal
brain indicate little or no distribution of intraventricularly
infused IGF-1 to subcortical white matter, cerebral cortex,
and perivascular spaces over 3 hr (Figs. 1A, 1B, and 5); the
patterns reported by Guan et al [37] are, thus, most prob-
ably abnormal and due to the pathological state. In sup-
port of this, in the experiments where the IGF-1 was
infused into the parenchyma and injured the tissue, much
of the radioactivity was found in the edematous corpus
callosum (Fig. 1C and 1D). The data in Figure 9 show that
IGF-1 does not move very far into normal gray matter and
illustrate the limits of such movement, probably mostly
diffusional, in control conditions. Seemingly, bulk flow of
CSF plus any edema fluid formed within the parenchyma
is needed to transport IGF-1 as widely as appears to be the
case in the hypoxia-ischemia model [37]. Of some rele-
vance to this, convection enhanced delivery of chemother-
apeutic agents infused directly into the parenchyma at
appreciable rates of volume flow are currently under
investigation in several laboratories and neurosurgical set-
tings [39,40].
Metabolism of IGF-1 in brain
Finally, the retention of the radiolabel on the parent com-
pound is always a problem in the interpretation of data
from studies such as ours. Proteases in many organs of the
body including brain have been shown to cleave IGF-1
into des(1–3)IGF-1 and the tripeptide, glycine-proline-
glutamate (GPE) [41]. It is possible that one or more of
these proteolytic products is no longer radiolabeled, is not
rapidly cleared from the system, does not permeate the
BBB, can diffuse great distances in brain tissue and reach
the appropriate receptors, and is active. Fitting with this
scheme, some reports have shown the beneficial effects of
intraventricularly injected active IGF-1 fragment in
experimental studies [42,43]. It was also felt that the
tripeptide GPE was more effective than its prohormone
IGF-1 [43]. If substantiated, then rapid removal of IGF-1
from the brain reported herein may be the reason for the
lesser effectiveness of this growth factor.
Conclusion
Further analyses of the normal flow of CSF and distribu-
tion of its entrained materials are needed for the compre-
hensive understanding of this system and its therapeutic
potential. Such studies may shed light on more appropri-
ate sites for intracerebral injections for accessing specific
regions and pathways within the brain via this system.
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